Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with a high selection rate of 93%, indicating a positive outlook for innovative companies in the sector [4][5] - The market sentiment has improved, driven by significant business development (BD) transactions, suggesting a continuation of the positive trend in 2026 despite potential short-term volatility [4] - The report emphasizes the importance of focusing on fundamentals and valuations when selecting stocks, particularly undervalued innovative companies that have been overlooked during market fluctuations [4] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, outperforming the broader market [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - As of February 10, 2026, domestic institutional holdings through Hong Kong Stock Connect slightly decreased to 22.2%, while foreign holdings increased to 39.7%, indicating a shift towards more positive sentiment among foreign investors [32] - Key increases in holdings were noted in leading CXO companies benefiting from demand recovery, such as Tigermed and WuXi AppTec [37][38] Valuation Overview - The report provides a valuation summary for various companies, with notable buy ratings for AstraZeneca, BeiGene, and others, indicating strong growth potential [3] - The average price-to-earnings (P/E) ratio for the healthcare sector is reported at 28.4 times, with specific segments like biopharmaceuticals at 13.1 times [16] Sales Trends - The report notes a 1% year-on-year decline in China's pharmaceutical market sales for 2025, with significant variations across different sales channels [5] - Public hospitals accounted for the largest market share but experienced a 2.1% decline, while retail pharmacies saw a 2.4% increase, driven by online sales growth [5] Procurement Insights - The recent national procurement round involved 316 commonly used drugs, with a high participation rate and diverse product offerings, ensuring stable clinical supply [5] - The procurement process has been refined to enhance quality and reliability, with stricter requirements for participating companies [5]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic partnership with Eli Lilly, marking its seventh collaboration and validating its antibody technology platform. This partnership is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue providing stable support for revenue growth [7][12]. - The management expects that three key assets, IBI363, IBI343, and IBI324, will enter global Phase III clinical trials, with IBI363 alone projected to contribute over USD 40 billion to the market [7][12]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12.505 billion, a decrease of 37.1% from previous estimates, while 2026 revenue is expected to rise to RMB 18.450 billion, an increase of 26.7% [3]. - Gross profit for 2025 is now forecasted at RMB 10.713 billion, down 41.0%, with a gross margin of 85.7%. For 2026, gross profit is expected to increase to RMB 16.064 billion, with a gross margin of 87.1% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1.055 billion, a decrease of 87.9%, while 2026 net profit is projected to rise to RMB 3.502 billion, reflecting a 37.8% increase [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][11]. Valuation Model - The DCF valuation model estimates the equity value at RMB 161.238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic collaboration with Eli Lilly, marking its seventh major partnership and validating its antibody technology platform. This collaboration is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its oncology and comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue supporting revenue growth [2][7]. - The report highlights the potential market space for key assets, estimating over USD 60 billion, with IBI363 alone contributing more than USD 40 billion. The company is also expected to introduce 8-10 new molecules annually from its innovation pipeline starting in 2026 [2][7]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12,505 million, a decrease of 37.1% from previous estimates. However, the 2026 revenue forecast has been increased by 26.7% to RMB 18,450 million, and the 2027 forecast has been raised by 18.6% to RMB 20,830 million [3]. - Gross profit for 2025 is now expected to be RMB 10,713 million, down 41.0% from prior estimates, while the gross profit margin is projected to be 85.7% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1,055 million, reflecting an 87.9% decrease from previous estimates, but is expected to rise to RMB 3,502 million in 2026 and RMB 4,341 million in 2027 [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][12]. Valuation Model - The discounted cash flow (DCF) valuation model estimates the equity value at RMB 161,238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].

Global Macro - The nomination of Kevin Warsh reflects a rebalancing of monetary policy under the constraints of the Trump 2.0 policy framework, aiming to enhance the alignment of monetary policy with growth and financing cost objectives [2] - Warsh's selection is seen as an optimal compromise, meeting Trump's criteria of being communicative, favoring low interest rates, and avoiding an immediate "independence crisis" narrative [2] - The significance of Warsh's nomination lies not in an immediate change in interest rates but in altering market expectations regarding the Federal Reserve's "toolbox weight" and "intervention boundaries," potentially triggering repricing of term premiums and volatility [2] Asset Implications - The interest rate curve is likely to steepen, with the Federal Reserve expected to tolerate higher long-term rates and risk asset volatility, leading to a scenario where short-term rates decrease while long-term rates remain stable or even rise [3] - The dollar may strengthen in the medium term, provided the narrative of independence is not compromised, despite potential interest rate cuts [3] - A systemic elevation in volatility is anticipated as the Federal Reserve gradually withdraws from micro-management, allowing asset prices to be determined more by fundamentals rather than liquidity illusions [3] Company Focus: NIO Inc. - NIO reported a positive earnings surprise for Q4 2025, with adjusted operating profit expected to reach between 700 million to 1.2 billion yuan, marking the first quarter of positive operating profit for the company [6] - This turning point is attributed to increased deliveries, a higher proportion of premium products, and cost reduction efforts, validating the operational leverage of its business model [6] - Looking ahead to 2026, while the first half may experience fluctuations in profit due to seasonal and cost pressures, the launch of new large SUV models in the second half is expected to boost gross margins, making the new vehicle cycle a key catalyst for valuation reassessment [6]

Investment Rating - The report maintains a "Buy" rating for Advanced Micro Devices (AMD US) with a target price of $275, indicating a potential upside of 37.4% from the current closing price of $200.19 [1][18]. Core Insights - The report emphasizes the strong execution in the data center segment, with expectations for significant growth in CPU and GPU demand. Management projects a compound annual growth rate (CAGR) of 60% for data center revenue over the next 3-5 years [2][7][8]. - AMD's recent quarterly performance exceeded expectations, with Q4 2025 revenue reported at $10.27 billion, a 34% year-over-year increase. The guidance for Q1 2026 revenue is set at $9.8 billion, reflecting a 32% year-over-year growth [7][13]. - The report highlights the anticipated launch of new products, including the Venice CPU and MI500 GPU series, which are expected to enhance AMD's competitive position in the market [7][8][11]. Financial Overview - Revenue projections for AMD are as follows: $25.79 billion in 2024, $34.64 billion in 2025, $46.73 billion in 2026, $64.63 billion in 2027, and $79.30 billion in 2028, with corresponding year-over-year growth rates of 13.7%, 34.3%, 34.9%, 38.3%, and 22.7% respectively [6][20]. - Non-GAAP net income is projected to reach $5.42 billion in 2024, $6.83 billion in 2025, $10.84 billion in 2026, $15.93 billion in 2027, and $19.74 billion in 2028, with significant growth rates [6][20]. - The report notes that AMD's gross margin is expected to remain strong, with a Non-GAAP gross margin of 55% projected for Q1 2026 [7][8]. Market Position and Competitive Landscape - AMD is expected to increase its market share in the data center CPU segment, driven by strong demand and the introduction of new products. The management's confidence in the data center business is reflected in the projected growth rates [7][8][11]. - The report also mentions potential competitive pressures from Intel and NVIDIA, which could impact AMD's market position. However, AMD's technological advantages in hardware configurations are expected to mitigate some of these risks [8][15].

Investment Rating - The report maintains a "Buy" rating for Rongchang Biologics (09995) with a target price of HKD 136 [1] Core Insights - The report is optimistic about the company's upcoming milestones, including the enrollment of MGIII for Taitasip and the initiation of SSIII, as well as the first overseas BLA submission for Vedisit and the data readout for 1LUCIII [1] - The inclusion of Taitasip's indications in the mainland's medical insurance is expected to drive significant sales growth, alongside the anticipated approvals for major indications like SS and IgAN [1] - Early-stage products (RC148, RC118, new ADCRC278) are progressing towards more indications, with data readouts likely to continue catalyzing the stock price [1] Financial Performance - Rongchang Biologics has issued a positive earnings forecast, expecting approximately RMB 3.25 billion in revenue for the previous year, representing a year-on-year growth of about 89% [1] - The net profit is projected to be around RMB 716 million, with a non-deductible net profit of approximately RMB 78.5 million, both showing a turnaround from losses year-on-year [1] - The performance significantly exceeded previous expectations from both the report and the market, with the timing of the profitability inflection point occurring earlier than previously anticipated [1] - Excluding contributions from external licensing and fair value gains, the report estimates that the company's core business achieved or approached breakeven in the fourth quarter, ahead of prior expectations [1] - With Taitasip and RC148 expanding internationally and more R&D costs being borne by overseas partners, there is optimism for further improvement in the company's profit margins this year [1]

Investment Rating - The report maintains a "Buy" rating for Great Wall Motors with a target price of HKD 22.5 [1] Core Insights - Great Wall Motors reported a revenue of RMB 222.79 billion for the previous year, representing a year-on-year growth of 10.2%. However, net profit decreased by 21.7% to RMB 9.912 billion, primarily due to the costs associated with direct sales channel development and the preemptive investment in new products and branding [1] - In Q4 of the previous year, the company achieved a record revenue of RMB 69.21 billion, but net profit fell to RMB 1.277 billion, a quarter-on-quarter decline of 44%. This decline was mainly attributed to a one-time provision for year-end bonuses (RMB 4.6 billion) along with increased expenditures on direct sales and advertising, as well as the ramp-up costs of new stores [1] - Looking ahead to 2026, the report suggests that the profitability of Great Wall Motors will depend on efficiency improvements, with overseas challenges expected to reach 600,000 units, which, along with enhanced direct sales efficiency, could drive profit recovery [1]

Investment Rating - The report assigns a "Buy" rating to several companies in the automotive sector, indicating an expectation of total returns exceeding the relevant industry over the next 12 months [8]. Core Insights - The automotive market in January 2026 experienced a seasonal downturn, with a notable decline in demand due to the impact of subsidy policies and adjustments in purchase tax. Most new energy vehicle manufacturers saw a significant month-on-month sales drop of 43.9% [3][4]. - Despite the overall weak performance in the first quarter of 2026, the continuation of the vehicle replacement policy is expected to support market recovery as local subsidy details are finalized [4]. - Companies to watch include: - Xpeng Motors (9868 HK/XPEV US) with new models launching and increasing overseas production [4]. - Geely Automobile (175 HK) focusing on internal resource integration post-privatization of Zeekr [4]. - BYD (1211 HK) benefiting from increased overseas production capacity and high growth in international sales [4]. Summary by Relevant Sections Sales Performance - BYD's January sales were 205,518 units, down 30.7% year-on-year and 50.4% month-on-month. However, exports surged by 43.3% to 100,009 units, with overseas sales accounting for 47.6% of total sales [6][7]. - NIO delivered 27,182 vehicles in January, a 96.1% year-on-year increase but a 43.5% month-on-month decline. The introduction of new financing options is expected to ease purchasing barriers [6][7]. - Xpeng delivered 20,011 vehicles, down 34.1% year-on-year and 46.6% month-on-month, with the new X9 model showing significant growth [6][7]. - Li Auto's deliveries were 27,668 units, reflecting a slight decline due to product cycle impacts [6][7]. - Xiaomi's deliveries exceeded 39,000 units, marking a 95% year-on-year increase [6][7]. Company Ratings and Price Targets - The report includes various companies with their respective ratings and target prices, indicating potential upside: - BYD (1211 HK) with a target price of 133.00, representing a 36.06% upside [8]. - NIO (9866 HK) with a target price of 62.75, indicating a 62.48% upside [8]. - Xpeng (9868 HK) with a target price of 134.69, suggesting an 87.98% upside [8].

Investment Rating - The report maintains a "Buy" rating for the company 瑞浦兰钧 (666 HK) with a target price of HKD 15.46, indicating a potential upside of 33.9% from the current closing price of HKD 11.54 [1][2][8]. Core Insights - The company is expected to achieve profitability in 2025, with a projected net profit of RMB 632 million, a significant turnaround from a loss of RMB 1.353 billion in 2024. This improvement is attributed to economies of scale and refined operational management [5]. - The global energy transition is anticipated to sustain high demand in the energy storage sector, with global energy storage battery shipments expected to reach 640 GWh in 2025, a year-on-year increase of 82.9% [5]. - The company plans to expand its production capacity to 90 GWh by 2025 and further to approximately 120 GWh and 150 GWh in 2026 and 2027, respectively, which is expected to enhance its economies of scale [5]. Financial Projections - Revenue projections for 2025 are set at RMB 22.372 billion, a 3% decrease from previous estimates, while 2026 revenue is expected to rise by 12% to RMB 30.502 billion [4]. - Gross profit for 2025 is forecasted at RMB 2.169 billion, with a gross margin of 9.7%, and is expected to improve to RMB 3.267 billion and a gross margin of 10.7% in 2026 [4]. - The net profit margin is projected to improve significantly, with a net profit of RMB 1.039 billion in 2026, translating to a net profit margin of 3.4% [4][5]. Market Position and Strategy - The company is strategically positioned in the household energy storage market, with a strong focus on high-value projects and a shift towards system integration products, which is expected to enhance the overall gross margin of the storage segment [5]. - The report highlights the importance of dynamic pricing mechanisms to mitigate the impact of rising raw material costs, particularly lithium carbonate, which has affected battery cell costs [5]. Valuation - Based on a DCF model, the company's equity value is estimated at RMB 36.444 billion, translating to a per-share value of HKD 17.33, with the target price set at HKD 15.46 corresponding to a 1.0x sales multiple for 2026 [6].

Market Overview - The market is transitioning from strong expectations to a "data verification" phase as the Spring Festival approaches, with a focus on marginal improvements in fundamental data[3] - Southbound capital continues to flow into the market, supporting Hong Kong stocks, which are expected to experience a "stock-heavy, index-light" structural market[3] Key Variables for February - Attention will be on post-Spring Festival consumption data, including tourism, dining, and real estate sales, which may reflect the effectiveness of the "resident income increase plan" and domestic demand expansion[4] - The upcoming "Two Sessions" will provide insights into fiscal policies, particularly regarding long-term special bonds and "new productivity," which could influence market sentiment towards infrastructure and technology sectors[4] - The market's confidence in the Fed's interest rate cuts may be affected by resilient U.S. inflation data, necessitating close monitoring of the dollar index's impact on Hong Kong stock liquidity[4] Sector Focus - Consumer and internet sectors are expected to benefit from positive Spring Festival data, with a focus on policy-driven areas like hospitality and food and beverage[5] - Hard technology and overseas manufacturing sectors are promising, particularly in semiconductors and consumer electronics, as well as leading companies in engineering machinery and home appliances[5] - Upstream resource products, such as copper and aluminum, are anticipated to perform well due to a recovering global manufacturing PMI and post-holiday inventory replenishment expectations[5] Stock Recommendations - **Cheung Kong Property Trust (778HK)**: Target price of HKD 5.92, potential upside of 15.9%, with a strong dividend yield over 7%[9] - **NVIDIA (NVDAUS)**: Target price of USD 245.00, potential upside of 27.3%, driven by sustainable AI demand[13] - **Hesai Technology (2525HK)**: Target price of HKD 269.66, potential upside of 35.0%, benefiting from L3 autonomous driving advancements[20] - **Sangfor Technologies (1530HK)**: Target price of HKD 39.50, potential upside of 65.1%, with strong growth prospects from core products[27] - **Midea Group (000333CH)**: Target price of HKD 96.20, potential upside of 23.5%, supported by robust market leadership and dividend policies[32] - **GCL-Poly Energy (3800HK)**: Target price of HKD 1.54, potential upside of 37.5%, benefiting from developments in perovskite technology and commercial aerospace[38]